Market by Product and Service, Type, Application, Technology, Industry Vertical, and Country Outlook | Forecast 2024-2032
Based on Triton’s research report, the Asia-Pacific multiplex assay market is set to witness growth at a CAGR of 9.34% over the forecasted period 2024-2032.
The countries examined in this region include:
• China
• Japan
• South Korea
• India
• ASEAN Countries
• Australia & New Zealand
• Rest of Asia-Pacific
A growing need for healthcare infrastructure, the proliferation of hospitals in emerging nations, and the advancement of research and development activities, fuel the expansion of the Asia-Pacific multiplex assay market. Additionally, healthcare reforms and technological progressions in the field contribute significantly to the studied market growth.
China captures the highest share in the multiplex assay market. The country’s proficiency in genomics, combinatorial chemistry, and HTS has positioned it as a prime destination for outsourced drug discovery endeavors. Additionally, increasing backing from industry stakeholders and government bodies is anticipated to propel the growth of cell-based assay technologies within China. A notable example is the development of a straightforward in vitro tumor chemosensitivity assay employing cell-penetrating peptides (CPPs) tagged luciferase (TAT-LUC). This initiative received financial support from the National Natural Science Foundation of China as part of the National Basic Research Program.
The growth of Japan’s market arises primarily from governmental initiatives aimed at fostering drug development and collaborative efforts among key industry players to advance multiplex assay tests. Key drivers include the escalating incidence of cancer and robust research and development (R&D) infrastructure. Notably, the Japanese government has allocated significant funds to R&D endeavors until 2030. Moreover, there’s an uptick in investments from international firms, which widens the scope of the multiple assay market across the nation.
Protein-based multiplex assays serve to identify and quantify proteins, playing a vital role in diagnosing diseases like cancer and infectious ailments. Furthermore, they facilitate the examination of protein functionalities and interactions, notably aiding clinical diagnostics and drug research in the pharmaceutical and biotechnology sectors.
The market is broadly segmented into type, product and service, technology, application, and industry vertical. The type segment is further divided into protein-based, nucleic acid-based, and other multiplex assays.
The notable companies in the market include Seegene Inc, Merck Millipore, Olink Proteomics AB, Qiagen NV, and Randox Laboratories Ltd.
Seegene Inc specializes in manufacturing molecular diagnostics systems, catering to the detection of viruses, bacteria, and various disease-causing agents. Its product range includes in vitro diagnostic reagents alongside automated systems for nucleic acid extraction, liquid handling workstations, and real-time diagnostic systems. Established in 2000, the company is headquartered in Seoul, South Korea.
KEY DELIVERABLES OF THE REPORT:
Market CAGR during the forecasting years 2024-2032
Detailed data highlighting key insights, industry components, and market strategies
Comprehensive information and estimation of the multiplex assay market revenue growth in the Asia-Pacific and its influence on the parent market
In-depth study of forthcoming trends in consumer behavioral patterns
A meticulous analysis of the competitive landscape and Porter’s Five Forces
A wide-ranging study of factors that will challenge the APAC multiplex assay market’s growth during the upcoming years
Want to get specific insights? Our team of analysts can customize this report based on your preferences. Connect with us here.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. ASIA-PACIFIC
MULTIPLEX ASSAY MARKET- SUMMARY
2. INDUSTRY
OUTLOOK
2.1. IMPACT
ANALYSIS ON THE MULTIPLEX ASSAY MARKET
2.1.1. IMPACT
OF COVID-19 ON THE MULTIPLEX ASSAY MARKET
2.2. PORTER’S
FIVE FORCES MODEL
2.2.1. THREAT
OF NEW ENTRANTS
2.2.2. THREAT
OF SUBSTITUTE PRODUCTS
2.2.3. BARGAINING
POWER OF BUYERS
2.2.4. BARGAINING
POWER OF SUPPLIERS
2.2.5. COMPETITIVE
RIVALRY
2.3. KEY
BUYING IMPACT ANALYSIS
2.3.1. ANALYTE
COVERAGE
2.3.2. SPEED
2.3.3. MULTIPLEXING
CAPABILITY
2.3.4. EASE
OF USE
2.3.5. AUTOMATION
2.4. MARKET
ATTRACTIVENESS INDEX
2.5. KEY
MARKET STRATEGIES
2.5.1. CONTRACTS
AND PARTNERSHIPS
2.5.2. BUSINESS
EXPANSIONS & DIVESTITURES
2.5.3. ACQUISITIONS
& MERGERS
2.5.4. PRODUCT
LAUNCHES & DEVELOPMENTS
2.6. MARKET
DRIVERS
2.6.1. ADOPTION
OF PERSONALIZED MEDICINES
2.6.2. HIGH
ADOPTION OF MULTIPLEX ASSAYS OVER TRADITIONAL METHODS
2.6.3. INCREASING
PREVALENCE OF CHRONIC DISEASES
2.7. MARKET
CHALLENGES
2.7.1. ISSUES
RELATED TO CROSS-REACTIVITY AND ASSAY INTERFERENCE
2.7.2. CHALLENGE
IN ACHIEVING ADEQUATE ASSAY RANGE
2.7.3. DEARTH
OF SKILLED PROFESSIONALS
2.8. MARKET
OPPORTUNITIES
2.8.1. TECHNOLOGICAL
ADVANCEMENTS IN ASSAY PLATFORMS
2.8.2. RAPID
GROWTH OF COMPANION DIAGNOSTICS
2.8.3. GROWTH
IN DRUG DISCOVERY INITIATIVES
2.9. ANALYST
PERSPECTIVE
3. ASIA-PACIFIC
MULTIPLEX ASSAY MARKET - BY PRODUCT AND SERVICE
3.1. REAGENTS
AND CONSUMABLES
3.2. INSTRUMENTS
AND ACCESSORIES
3.3. SOFTWARE
AND SERVICES
4. ASIA-PACIFIC
MULTIPLEX ASSAY MARKET - BY TYPE
4.1. PROTEIN-BASED
MULTIPLEX ASSAY
4.2. NUCLEIC
ACID-BASED MULTIPLEX ASSAY
4.3. OTHER
MULTIPLEX ASSAYS
5. ASIA-PACIFIC
MULTIPLEX ASSAY MARKET - BY APPLICATION
5.1. RESEARCH
AND DEVELOPMENT
5.2. CLINICAL
DIAGNOSTICS
5.3. COMPANION
DIAGNOSTICS
6. ASIA-PACIFIC
MULTIPLEX ASSAY MARKET - BY TECHNOLOGY
6.1. MULTIPLEX
PROTEIN MICROARRAY
6.2. MULTIPLEX
PCR
6.3. OTHER
TECHNOLOGIES
7. ASIA-PACIFIC
MULTIPLEX ASSAY MARKET - BY INDUSTRY VERTICAL
7.1. PHARMACEUTICAL
& BIOTECHNOLOGY COMPANIES
7.2. RESEARCH
INSTITUTES
7.3. CLINICAL
LABORATORIES
7.4. HOSPITALS
8. ASIA-PACIFIC
MULTIPLEX ASSAY MARKET – BY COUNTRY OUTLOOK
8.1. CHINA
8.1.1. CHINA
MULTIPLEX ASSAYS MARKET FORECAST & PROSPECTS
8.2. JAPAN
8.2.1. JAPAN
MULTIPLEX ASSAYS MARKET FORECAST & PROSPECTS
8.3. INDIA
8.3.1. INDIA
MULTIPLEX ASSAYS MARKET FORECAST & PROSPECTS
8.4. ASEAN
COUNTRIES
8.4.1. ASEAN
COUNTRIES MULTIPLEX ASSAYS MARKET FORECAST & PROSPECTS
8.5. AUSTRALIA
& NEW ZEALAND
8.5.1. AUSTRALIA
& NEW ZEALAND MULTIPLEX ASSAYS MARKET FORECAST & PROSPECTS
8.6. SOUTH
KOREA
8.6.1. SOUTH
KOREA MULTIPLEX ASSAYS MARKET FORECAST & PROSPECTS
8.7. REST
OF ASIA-PACIFIC
8.7.1. REST
OF ASIA-PACIFIC MULTIPLEX ASSAYS MARKET FORECAST & PROSPECTS
9. COMPETITIVE
LANDSCAPE
9.1. ABCAM
LIMITED
9.1.1. OVERVIEW
9.1.2. PRODUCT
PORTFOLIO
9.2. AGILENT
TECHNOLOGIES INC
9.2.1. OVERVIEW
9.2.2. PRODUCT
PORTFOLIO
9.2.3. KEY
STRENGTHS
9.2.4. KEY
CHALLENGES
9.3. BECTON
DICKINSON AND COMPANY (BD)
9.3.1. OVERVIEW
9.3.2. PRODUCT
PORTFOLIO
9.3.3. KEY
STRENGTHS
9.3.4. KEY
CHALLENGES
9.4. BIO-RAD
LABORATORIES INC
9.4.1. OVERVIEW
9.4.2. PRODUCT
PORTFOLIO
9.4.3. KEY
STRENGTHS
9.4.4. KEY
CHALLENGES
9.5. BIO-TECHNE
CORPORATION
9.5.1. OVERVIEW
9.5.2. PRODUCT
PORTFOLIO
9.6. F.
HOFFMANN-LA ROCHE LTD
9.6.1. OVERVIEW
9.6.2. PRODUCT
PORTFOLIO
9.6.3. KEY STRENGTHS
9.6.4. KEY CHALLENGES
9.7. ILLUMINA
INC
9.7.1. OVERVIEW
9.7.2. PRODUCT
PORTFOLIO
9.7.3. KEY STRENGTHS
9.7.4. KEY CHALLENGES
9.8. MERCK
MILLIPORE
9.8.1. OVERVIEW
9.8.2. PRODUCT
PORTFOLIO
9.9. OLINK
PROTEOMICS AB
9.9.1. OVERVIEW
9.9.2. PRODUCT
PORTFOLIO
9.10. QIAGEN
NV
9.10.1. OVERVIEW
9.10.2. PRODUCT
PORTFOLIO
9.10.3. KEY STRENGTHS
9.10.4. KEY CHALLENGES
9.11. RANDOX
LABORATORIES LTD
9.11.1. OVERVIEW
9.11.2. PRODUCT
PORTFOLIO
9.12. SEEGENE
INC
9.12.1. OVERVIEW
9.12.2. PRODUCT
PORTFOLIO
9.13. SIEMENS
HEALTHINEERS AG
9.13.1. OVERVIEW
9.13.2. PRODUCT
PORTFOLIO
9.13.3. KEY
STRENGTHS
9.13.4. KEY
CHALLENGES
9.14. THERMO
FISHER SCIENTIFIC INC
9.14.1. OVERVIEW
9.14.2. PRODUCT
PORTFOLIO
9.14.3. KEY
STRENGTHS
9.14.4. KEY
CHALLENGES
10. RESEARCH
METHODOLOGY & SCOPE
10.1. RESEARCH
SCOPE & DELIVERABLES
10.2. SOURCES
OF DATA
10.3. RESEARCH
METHODOLOGY
TABLE
1: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY COUNTRY OUTLOOK, HISTORICAL YEARS,
2020-2023 (IN $ MILLION)
TABLE
2: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY COUNTRY OUTLOOK, FORECAST YEARS,
2024-2032 (IN $ MILLION)
TABLE
3: CONTRACTS AND PARTNERSHIPS
TABLE
4: LIST OF BUSINESS EXPANSIONS & DIVESTITURES
TABLE
5: ACQUISITIONS & MERGERS
TABLE
6: LIST OF NEW PRODUCT LAUNCHES & DEVELOPMENTS
TABLE
7: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY PRODUCT AND SERVICE, 2024-2032 (IN $
MILLION)
TABLE
8: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY TYPE, 2024-2032 (IN $ MILLION)
TABLE
9: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024-2032 (IN $
MILLION)
TABLE
10: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024-2032 (IN $ MILLION)
TABLE
11: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY INDUSTRY VERTICAL, 2024-2032 (IN $
MILLION)
TABLE
12: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY COUNTRY OUTLOOK, 2024-2032 (IN $
MILLION)
FIGURE
1: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY PRODUCT AND SERVICE, 2023 &
2032, (IN %)
FIGURE
2: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY REAGENTS AND CONSUMABLES, 2024-2032
(IN $ MILLION)
FIGURE
3: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY INSTRUMENTS AND ACCESSORIES,
2024-2032 (IN $ MILLION)
FIGURE
4: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY SOFTWARE AND SERVICES, 2024-2032 (IN
$ MILLION)
FIGURE
5: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY TYPE, 2023 & 2032 (IN %)
FIGURE
6: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY PROTEIN-BASED MULTIPLEX ASSAY,
2024-2032 (IN $ MILLION)
FIGURE
7: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY NUCLEIC ACID-BASED MULTIPLEX ASSAY,
2024-2032 (IN $ MILLION)
FIGURE
8: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY OTHER MULTIPLEX ASSAYS, 2024-2032
(IN $ MILLION)
FIGURE
9: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY APPLICATION, 2023 & 2032 (IN %)
FIGURE
10: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY RESEARCH AND DEVELOPMENT, 2024-2032
(IN $ MILLION)
FIGURE
11: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY CLINICAL DIAGNOSTICS, 2024-2032 (IN
$ MILLION)
FIGURE
12: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY COMPANION DIAGNOSTICS, 2024-2032
(IN $ MILLION)
FIGURE
13: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2023 & 2032 (IN %)
FIGURE
14: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY MULTIPLEX PROTEIN MICROARRAY,
2024-2032 (IN $ MILLION)
FIGURE
15: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY MULTIPLEX PCR, 2024-2032 (IN $
MILLION)
FIGURE
16: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY OTHER TECHNOLOGIES, 2024-2032 (IN $
MILLION)
FIGURE
17: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY INDUSTRY VERTICAL, 2023 & 2032
(IN %)
FIGURE
18: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY
COMPANIES, 2024-2032 (IN $ MILLION)
FIGURE
19: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY RESEARCH INSTITUTES, 2024-2032 (IN
$ MILLION)
FIGURE
20: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY CLINICAL LABORATORIES, 2024-2032
(IN $ MILLION)
FIGURE
21: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY HOSPITALS, 2024-2032 (IN $ MILLION)
FIGURE
22: ASIA-PACIFIC MULTIPLEX ASSAY MARKET, BY COUNTRY OUTLOOK, 2023 & 2032
(IN %)
FIGURE
23: CHINA MULTIPLEX ASSAY MARKET 2024-2032 (IN $ MILLION)
FIGURE
24: JAPAN MULTIPLEX ASSAY MARKET 2024-2032 (IN $ MILLION)
FIGURE
25: INDIA MULTIPLEX ASSAY MARKET 2024-2032 (IN $ MILLION)
FIGURE
26: ASEAN COUNTRIES MULTIPLEX ASSAY MARKET 2024-2032 (IN $ MILLION)
FIGURE
27: AUSTRALIA & NEW ZEALAND MULTIPLEX ASSAY MARKET 2024-2032 (IN $ MILLION)
FIGURE
28: SOUTH KOREA MULTIPLEX ASSAY MARKET 2024-2032 (IN $ MILLION)
FIGURE
29: REST OF ASIA-PACIFIC MULTIPLEX ASSAY MARKET 2024-2032 (IN $ MILLION)